MedTrace Logo

Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone

NCT04232761 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 194

Last updated 2024-07-17

No results posted yet for this study

Summary

In this observational study researchers want to gather more information about safety and survival in patients suffering from castration-resistant prostate cancer (CRPC) which has spread to the bone and were treated with radium-223 in routine clinical practice in Taiwan. Radium-223 (Ra-223) is an alpha particle-emitting radioactive agent approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

  • Castration-resistant Prostate Cancer

Interventions

DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Drug administration as determined by treating physician

Sponsors & Collaborators

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-07
Primary Completion
2024-04-29
Completion
2024-04-29

Countries

  • Taiwan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04232761 on ClinicalTrials.gov